IOVANCE BIOTHERAPEUTICS FILES 8-K
Ticker: IOVA · Form: 8-K · Filed: Mar 4, 2024 · CIK: 1425205
| Field | Detail |
|---|---|
| Company | Iovance Biotherapeutics, Inc. (IOVA) |
| Form Type | 8-K |
| Filed Date | Mar 4, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.000041666 |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, corporate-reporting
Related Tickers: IOVA
TL;DR
IOVA files routine 8-K, no major news.
AI Summary
On March 4, 2024, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or other significant business updates detailed in the provided text.
Why It Matters
This filing indicates routine corporate reporting, likely related to financial statements or exhibits, without immediate news impacting the company's operations or stock.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, not indicating any immediate risks or significant events.
Key Players & Entities
- IOVANCE BIOTHERAPEUTICS, INC. (company) — Registrant
- March 4, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-36860 (identifier) — Commission File Number
- 75-3254381 (identifier) — I.R.S. Employer Identification No.
- 825 Industrial Road, Suite 400 (address) — Business Address
- San Carlos (location) — City
FAQ
What is the primary purpose of this 8-K filing by IOVANCE BIOTHERAPEUTICS, INC.?
The filing is a Current Report on Form 8-K, primarily concerning 'Other Events' and 'Financial Statements and Exhibits'.
When was this 8-K report filed?
The report was filed on March 4, 2024.
In which state is IOVANCE BIOTHERAPEUTICS, INC. incorporated?
The company is incorporated in Delaware.
What is the Commission File Number for IOVANCE BIOTHERAPEUTICS, INC.?
The Commission File Number is 001-36860.
What is the business address listed for IOVANCE BIOTHERAPEUTICS, INC.?
The business address is 825 Industrial Road, Suite 400, San Carlos, CA 94070.
Filing Stats: 433 words · 2 min read · ~1 pages · Grade level 8.7 · Accepted 2024-03-04 08:00:20
Key Financial Figures
- $0.000041666 — h registered Common stock, par value $0.000041666 per value IOVA The Nasdaq Stock Marke
Filing Documents
- tm247846d1_8k.htm (8-K) — 26KB
- tm247846d1_ex99-1.htm (EX-99.1) — 14KB
- tm247846d1_ex99-1img001.jpg (GRAPHIC) — 13KB
- 0001104659-24-030249.txt ( ) — 232KB
- iova-20240304.xsd (EX-101.SCH) — 3KB
- iova-20240304_lab.xml (EX-101.LAB) — 33KB
- iova-20240304_pre.xml (EX-101.PRE) — 22KB
- tm247846d1_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On March 4, 2024, Iovance Biotherapeutics, Inc. issued a press release announcing a clinical program update for the IOV-LUN-202 registrational trial investigating LN-145 TIL cell therapy in non-small cell lung cancer. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
01. Financial
Item 9.01. Financial (d) Exhibits. Exhibit Number Description 99.1 Press Release dated March 4, 2024. 104 Cover Page Interactive Data File, formatted in Inline XBRL and included as Exhibit 101
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Iovance Biotherapeutics, Inc. Dated: March 4, 2024 By: /s/ Frederick G. Vogt Name: Frederick G. Vogt, Ph.D., J.D. Title: Interim CEO and General Counsel